How to Perform Glycan Structural Analysis for Antibody Drugs?
-
ADCC (antibody-dependent cellular cytotoxicity) activity: removal of core fucose enhances ADCC.
-
CDC (complement-dependent cytotoxicity) function: glycan composition influences C1q binding.
-
Half-life and stability: sialylation affects in vivo clearance rates.
-
PNGase F: the standard method for cleaving Fc N-glycans.
-
PNGase A: applied to enzyme-resistant N-glycans, such as those containing α1,3-fucose.
- For O-glycosylation or certain atypical N-glycans, chemical strategies (e.g., β-elimination) may be employed, though their application in Fc analysis is limited.
-
Reverse-phase LC (RP-LC): used to assess glycopeptide heterogeneity.
-
Hydrophilic interaction LC (HILIC): separates derivatized glycans, suitable for quantitative analyses.
-
MALDI-TOF-MS: rapid evaluation of glycan mass distribution, enabling high-throughput screening.
-
LC-ESI-MS/MS: combines LC separation with MS for glycan structural analysis and site-specific identification.
-
Top-down / Bottom-up Strategies: Top-down assesses intact antibody glycoform distributions, whereas Bottom-up digests antibodies into peptides for site-specific glycoform characterization.
Monoclonal antibody therapeutics (mAbs), owing to their high specificity and therapeutic potential, have become central products in modern biopharmaceuticals. The bioactivity, half-life, and immunogenicity of antibodies are often significantly modulated by glycosylation. Variations in glycan structures can influence both therapeutic efficacy and safety. Therefore, comprehensive glycan characterization is a critical component in antibody research, development, manufacturing, and quality control.
Overview of Antibody Glycosylation
In antibodies, particularly IgG molecules, glycosylation predominantly occurs at the Fc region Asn297 site and can occasionally be present in the Fab region. Typical glycan types include high-mannose, complex-type, galactose-deficient forms (G0/G1/G2), and aberrant glycoforms such as sialylated species. Glycan modifications directly modulate:
Accurate glycan profiling is therefore essential for both drug development and quality control.
Core Workflow for Antibody Glycan Structural Analysis
The structural analysis of antibody glycans typically comprises four major stages: glycan release, derivatization and labeling, separation and detection, and data analysis.
1. Glycan Release
Glycan release is the initial step, determining the integrity and accuracy of downstream analysis. Common approaches include:
(1) Enzymatic Release
(2) Chemical Release
2. Glycan Derivatization and Labeling
Glycans produce low signals in MS and LC analyses; derivatization is commonly employed to enhance detectability:
(1) Fluorescent labeling (2-AB, 2-AA): improves HPLC/UPLC separation resolution and detection sensitivity.
(2) Permethylation: increases MS signal intensity and stabilizes glycans for analysis.
3. Separation and Detection
Separation and detection are central to glycan analysis. The main methodologies include:
(1) HPLC/UPLC Separation
(2) Mass Spectrometry (MS) Analysis
4. Data Analysis and Structural Assignment
Due to the complexity and heterogeneity of antibody glycans, data analysis is crucial:
(1) Spectrum matching: glycoforms are identified using specialized software (e.g., Byonic, GlycoWorkbench).
(2) Quantitative analysis: glycoform percentages are determined based on fluorescence or MS signal intensity.
(3) Quality control: glycoform profiles are compared with standards to detect deviations or abnormalities.
Applications of Antibody Glycan Structural Analysis
Glycan characterization serves as both a quality control measure and a tool to inform multiple aspects of antibody therapeutics:
1. Efficacy Evaluation
Assessment of core fucose content and sialylation levels to predict ADCC/CDC activity changes.
2. Batch Consistency Control
Comparison of glycan profiles across production batches to ensure clinical consistency and safety.
3. Biosimilar Development
Glycan similarity to the reference product is an essential parameter for biosimilar evaluation.
4. Disease-Associated Glycomics
Fc glycoform aberrations correlate with autoimmune diseases, cancer, and infectious diseases, providing potential biomarkers.
Antibody glycan structural analysis is a cornerstone for biopharmaceutical R&D, quality control, and glycomics research. Core methodologies include enzymatic release, derivatization, separation and detection, and data analysis. MtoZ Biolabs integrates high-resolution MS platforms, optimized enzymatic workflows, and automated data analysis pipelines, delivering high coverage, precise quantification, and traceable reporting. Whether for the development of novel antibody therapeutics or batch quality assessment, MtoZ Biolabs provides reliable technical support for research and manufacturing.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
